Last reviewed · How we verify
cisplatin and paclitaxel — Competitive Intelligence Brief
phase 3
Platinum-based chemotherapy, Taxane
Oncology
Small molecule
Live · refreshed every 30 min
Target snapshot
cisplatin and paclitaxel (cisplatin and paclitaxel) — Henan Cancer Hospital. Cisplatin works by crosslinking DNA, thereby inhibiting DNA replication and transcription, while paclitaxel stabilizes microtubules, preventing cell division.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| cisplatin and paclitaxel TARGET | cisplatin and paclitaxel | Henan Cancer Hospital | phase 3 | Platinum-based chemotherapy, Taxane |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape (Platinum-based chemotherapy, Taxane class)
- Henan Cancer Hospital · 1 drug in this class
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- cisplatin and paclitaxel CI watch — RSS
- cisplatin and paclitaxel CI watch — Atom
- cisplatin and paclitaxel CI watch — JSON
- cisplatin and paclitaxel alone — RSS
- Whole Platinum-based chemotherapy, Taxane class — RSS
Cite this brief
Drug Landscape (2026). cisplatin and paclitaxel — Competitive Intelligence Brief. https://druglandscape.com/ci/cisplatin-and-paclitaxel. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab